Endo International plc
Glandore Business Centres
No. 33 Fitzwilliam Square
Tel: 353-1-669-8559 or 800-462-3636
192 articles with Endo International plc
Results on November 5, 2019 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET before the U.S. financial markets open.
Endo International plc announced the successful culmination of two litigation matters before the U.S. District Court for the District of Columbia regarding the unlawful compounding of vasopressin from bulk drug substances.
Endo Announces Submission of Biologics License Application to FDA for Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
Endo International plc (NASDAQ: ENDP) announced today that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.
Endo had previously announced a settlement in principle of the Track 1 Cases on August 20, 2019.
Endo to Present New XIAFLEX® (collagenase clostridium histolyticum) Data at the 2019 American Society for Surgery of the Hand's (ASSH) Annual Meeting
Endo International plc announced that four new studies of XIAFLEX®, including real-world data, for the treatment of Dupuytren's contracture will be presented as ePosters at the 74th Annual Meeting of the American Society for Surgery of the Hand in Las Vegas, Nevada, September 5 - 7, 2019.
Endo's operating company Par Pharmaceutical, Inc. expects to distribute the product through specialty pharmacies beginning this month.
Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Delayed-release Tablets in the United States
Endo International plc announced that one of its operating companies, Par Pharmaceutical, has begun shipping an authorized generic version of Merck's Noxafil® delayed-release tablets, 100 mg.
In light of recent media coverage and inquiries, Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. (collectively, the "Endo Entities") have reached a settlement in principle with the County of Cuyahoga, Ohio,
Endo International plc (NASDAQ: ENDP) today reported second-quarter 2019 financial results, including:
Endo Applauds U.S. District Court Decision that Vasopressin Cannot be Used for Compounding by Outsourcing Facilities
Endo International plc applauded the U.S. District Court for the District of Columbia's decision supporting the Food and Drug Administration's determination that vasopressin cannot be used for compounding by outsourcing facilities.
Endo Appoints Domenico Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics
Endo International plc announced the appointment of Domenic Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics, effective immediately.
Endo International plc (NASDAQ: ENDP) and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, are pleased to announce today that Endo International plc's subsidiary Endo Ventures Limited has entered into definitive agreements with Helsinn
Endo International plc (NASDAQ: ENDP) will announce its second-quarter 2019 financial results on August 6, 2019 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET before the U.S. financial markets open.
Nationally Recognized Urologist and Author, Aaron Spitz, MD, Teams Up with Endo Pharmaceuticals' Ask About the Curve Campaign to Encourage Men to Get "In Touch" With Their Anatomy This Men's Health Month
Ask About the Curve raises awareness of Peyronie's disease, a men's health condition that may affect about 1 in 10 men and leads to a pronounced curvature in the penis and potential pain during arousal.
Phase 3 Data of Collagenase Clostridium Histolyticum for the Investigational Treatment of Cellulite to Be Presented at The Aesthetic Meeting 2019
Clinical Investigator Dr. Lawrence Bass is a Featured Hot Topics Speaker
Endo International plc announced that members of management will participate in a fireside chat at the RBC Annual Healthcare Conference in New York City on Tuesday, May 21, 2019 at 10:00 a.m. ET.
Endo International plc reported first-quarter 2019 financial results
Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product
One vial of product was observed containing a glass fragment after reconstitution.
Endo International plc will announce its first-quarter 2019 financial results on May 9, 2019 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET before the U.S. financial markets open.
Endo Begins Shipment of Authorized Generic Version of PROVENTIL® (albuterol sulfate) HFA Inhalation Aerosol in the United States
Endo International plc announced that one of its operating companies, Par Pharmaceutical, has begun shipping an authorized generic version of Merck's PROVENTIL® HFA Inhalation Aerosol, 120mcg.